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Association of Polymorphisms in
Pulmonary Surfactant Protein A1 and A2
Genes With High-Altitude Pulmonary
Edema*
Shweta Saxena, MSc; Ratan Kumar, PhD; Taruna Madan, PhD;
Vanita Gupta, BSc; Kambadur Muralidhar, PhD; and Puranam U. Sarma, PhD
Study objectives: A potential pathogenetic cofactor for the development of high-altitude pulmo-
nary edema (HAPE) is an increase in capillary permeability, which could occur as a result of an
inflammatory reaction and/or free-radical-mediated injury to the lung. Pulmonary surfactant
protein A (SP-A), the most abundant surfactant protein, has potent antioxidant properties and
protects unsaturated phospholipids and growing cells from oxidative injury. Single-nucleotide
polymorphisms (SNPs) in SP-A1 and SP-A2, genes encoding SP-A, have been associated with
susceptibility to respiratory distress syndrome, COPD, and pulmonary infections. In view of the
protective role of SP-A against inflammatory reactions and oxidative damage, the two underlying
mechanisms in development of HAPE, we examined the association of constitutional susceptibil-
ity to HAPE with polymorphisms in SP-A1 and SP-A2.
Design: A cross-sectional case-control study.
Setting: Blood samples were collected at an altitude (> 3,500 m).
Participants: Twelve low-altitude native (LAN) subjects with a history of HAPE, 15 healthy LAN
sojourners without a history of HAPE (LAN control subjects), and 19 healthy high-altitude natives
(HANs) without a history of HAPE (HAN control subjects).
Measurements: The SNPs in four exons and intermediate introns of the SP-A1 and SP-A2 were
screened by polymerase chain reaction and sequencing. Biochemical parameters related to
oxidative stress (malondialdehyde and reduced glutathione in RBC) and membrane permeability
(circulating levels of lactate dehydrogenase) were measured in plasma.
Results: Allele frequencies of three loci in SP-A1 and one in SP-A2 were significantly different
between LAN HAPE patients (SP-A1 C1101T: C allele, 36.4% and T allele, 63.6%; SP-A1 T3192C:
T allele, 61.1% and C allele, 38.9%; SP-A1 T3234C: T allele, 61.1% and C allele, 38.9%; and SP-A2
A3265C: A allele, 21.4% and C allele, 78.6%) and LAN control subjects (SP-A1 C1101T: C allele,
8.3% and T allele, 91.7%; SP-A1 T3192C: T allele, 15% and C allele, 85%; SP-A1 T3234C: T allele,
15% and C allele, 85%; and SP-A2 A3265C: A allele, 37.5% and C allele, 62.5%) [C1101T odds
ratio [OR], 6.3 with 95% confidence interval (CI), 2.8 to 14.3; T3192C OR, 8.9 with 95% CI, 4.5
to 17.6; T3234C OR, 8.9 with 95% CI, 4.5 to 17.6; and A3265C OR, 2.2 with 95% CI, 1.2 to 4.1
(p < 0.01)]. Heterozygous individuals, with respect to SP-A1 C1101T and SP-A2 A3265C, showed
less severity in oxidative damage in comparison with homozygous subjects (SP-A1 T1101 and
SP-A2 C3265).
Conclusion: The polymorphisms in SP-A1 (C1101T, T3192C, and T3234C) and SP-A2 (A3265C)
might be one of the genetic factors contributing to susceptibility to HAPE.
(CHEST 2005; 128:1611–1619)
Key words: genetic predisposition; high-altitude pulmonary edema; oxidative damage; single-nucleotide polymor-
phisms; SP-A1; SP-A2
Abbreviations: CI  confidence interval; GSH reduced glutathione; HAN high-altitude native; HAPE high-
altitude pulmonary edema; LAN low-altitude native; LDH lactate dehydrogenase; MDA malondialdehyde;
OR  odds ratio; PCR  polymerase chain reaction; SNP single-nucleotide polymorphism; SP-A pulmonary
surfactant protein A; SP-A1 C1101T single-nucleotide polymorphism between C and T alleles at 1101 base pair in
SPA1 gene
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P eople, who rapidly ascend to high altitude andwho are unable to acclimatize, suffer from high-
altitude pulmonary edema (HAPE).1 The pathophys-
iology of HAPE, a multifactorial and life-threatening
disease, is complex, and reinductees are more sus-
ceptible to the disease.2,3 A potential pathogenetic
cofactor for the development of HAPE is an increase
in capillary permeability, which could occur as a
result of an inflammatory reaction and/or free-radi-
cal-mediated injury to the lung. A protective role for
alveolar surfactant in HAPE was identified very
early.4 Droma et al5 observed that the pulmonary
surfactant in HAPE subjects not only lined the
alveolar surface but was also patchily distributed
within alveoli. Pulmonary surfactant protein A (SP-A),
the most abundant surfactant protein, has a regula-
tory role in pulmonary surfactant secretion and
recycling.6 Bridges et al7 have shown that SP-A has
potent antioxidant properties and protects unsatur-
ated phospholipids and growing cells from oxidative
injury. Polymorphisms in SP-A1 and SP-A2, genes
encoding lung surfactant protein A, have been asso-
ciated with susceptibility to respiratory distress syn-
drome, COPD, and pulmonary infections.8–11 SP-A
gene variants on ozone exposure produced signifi-
cantly different amounts of proinflammatory cyto-
kines interleukin 8 and tumor necrosis factor .12
Genetic susceptibility has been suggested in the
development of HAPE, and positive associations
have been reported13,14 with HLA-DR6, HLA-DQ4,
and endothelial nitric oxide synthase genes. In view
of the protective role of SP-A against inflammatory
reactions and oxidative damage, the two underlying
mechanisms in the development of HAPE, we ex-
amined the association of polymorphisms in SP-A1
and SP-A2 genes with HAPE for the first time.
Because the high-altitude native (HAN) population
is proposed to be relatively resistant to HAPE, the
HAN controls were also studied to determine
whether the alleles that are determining susceptibil-
ity to HAPE in low-altitude native (LAN) popula-
tions are in low frequency in the HAN population.
Biochemical parameters related to oxidative stress,
such as circulating malondialdehyde (MDA), an in-
dicator of free-radical-induced lipid peroxidation,
RBC-reduced glutathione (GSH), an indicator of
antioxidant levels, and lactate dehydrogenase (LDH),
an indicator of altered cell membrane permeability, are
reported to participate in the course of HAPE.15 The
effect of variant genotypes on the oxidative damage was
evaluated by a comparative analysis of these biochem-
ical parameters.
Materials and Methods
Subjects
The study population consisted of 46 age-matched male vol-
unteers. All of the subjects were unrelated natives of India.
Written informed consent was obtained from each subject after a
full explanation of the study, which was approved by the human
ethics committee of the Defense Institute of Physiology and
Allied Sciences, Defense Research and Development Organiza-
tion. LAN sojourners who suffered from HAPE at high altitude
were brought to the hospital (at 3,500 m) immediately after the
onset of symptoms. The blood samples were drawn from the
HAPE patients within 2 to 3 days of occurrence of the symptoms.
At the time of collection of the samples, the HAPE patients were
still ill and under treatment in the hospital. The mean ( SE)
age, height, and weight of volunteers were 28.8 1.5 years,
170  0.7 cm, and 59.8 0.9 kg, respectively. The subjects were
categorized in three groups, as described below.
The first group was composed of 15 healthy LAN control
subjects, that is, those who did not suffer either from HAPE on
exposure ( 1 month) to a high altitude ( 3,500 m) or any
medical problems related to altitude or cardiopulmonary disor-
ders. The second group consisted of 12 LAN subjects who
suffered from HAPE at high altitude ( 3,500 m). All of these
subjects showed presence of most of the clinical features,
including shortness of breath, vomiting, progressive dyspnea,
chest pain, fever, frothy pink expectoration, cyanosis of lips, and
weakness at the onset of the disorder. The radiograph findings
confirmed the pulmonary infiltrates. All of the patients recovered
promptly with treatment. The effective treatment for the HAPE
patients was bed rest, supplemental oxygen, and diuretics. The
third group consisted of 19 HAN control subjects ( 3,500 m)
who never suffered from HAPE.
Genomic DNA Isolation
Genomic DNA was extracted from peripheral blood mononu-
clear cells following a previously described protocol.16 Purified
genomic DNA samples were used as templates in the polymerase
chain reaction (PCR) amplification of various regions of SP-A1
and SP-A2.
PCR
For specific amplification and economical use of DNA sam-
ples, two rounds of PCR amplification were carried out for SP-A1
and SP-A2. The first round of PCR amplified the complete SP-A1
and SP-A2 genes separately (primer 1/2 for SP-A1 and primer 3/2
for SP-A2). The PCR conditions were 95°C/2, 33 cycles of
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95°C/30, 58°C/30, 72°C/3, and final extension for 72°C/5. The
PCR products of first round were diluted (1:50) with water (Milli
Q Millipore; Millipore S.A. 67120 Molsheim, France) and used as
templates to amplify different regions of SP-A1 and SP-A2.17 The
details of the primers used for amplification are shown in Table
1. Amplification conditions for other PCRs were similar to those
given above except the specific annealing temperatures, as
follows: 60°C for primer pairs 6/7 and 8/9; 59.8°C for primer
pairs 12/13 and 14/15, and 70°C for primer pair 16/17. The PCR
conditions for primer pairs 4/5 and 10/11 were 95°C/2, 5 cycles
of 95°C/30, 50°C/1, 70°C/1, 27 cycles of 95°C/30, 55°C/1,
70°C/1, and final extension for 72°C/5.
Purification of PCR Products and Sequencing
The PCR products were purified and sequenced following a
previously described protocol.11
Determination of Biochemical Parameters
The thiobarbituric acid-reactive MDA and RBC-reduced GSH
levels were measured by standard methods.18,19 Circulating
plasma LDH activity was estimated by opt. kits (LD; Randox
Laboratories Ltd; Antrim, UK).
Statistical Analysis
Allele frequencies at variable loci of SP-A1 and SP-A2 among
different groups of subjects were compared by a 2 2 table,
Fisher exact test, and statistical power tools using an online
statistical analysis tool (http://home.clara.net/sisa). The odds ratio
(OR) and p value were calculated at 95% confidence interval
(CI). The biochemical parameters were analyzed for statistical
significance using one-way analysis of variance, and pairwise
comparisons were made by the Bonferroni multiple range test.
Results
Eight loci in SP-A1 (C1101T, C1162T, C1193G,
C1416T, G1544A, T3138C, T3192C, and T3234C)
and eight loci in SP-A2 (C1382G, T1492C, G1649C,
A1660G, C2474T, A2491C, T3018C, and A3265C)
were found to be polymorphic in the study groups
(Table 2). LAN HAPE patients showed significant
differences (p 0.01) in the frequencies of three
single-nucleotide polymorphisms (SNPs) in SP-A1
(C1101T: OR, 6.3 [95% CI, 2.8 to 4.3]; T3192C: OR,
8.9 [95% CI, 4.5 to 17.6]; and T3234C: OR, 8.9 [95%
CI, 4.5 to 17.6]) and one SNP in SP-A2 (A3265C:
OR, 2.2 [95% CI, 1.2 to 4.1]) in comparison with the
LAN control subjects (Table 3) using a 2 2 table
analysis. At a threshold for  (type 1 error probabil-
ity) of 5%, our study will have around 80% power to
detect SNP with a prevalence of  20%, resulting in
an increase in the relative risk of disease of at least
2.2 to 8.9. At 50% retrospective power of the test, the
minimal detectable differences for these statistical
analyses are 0.28, 0.46, 0.46, and 0.16, respectively.
The SP-A1 T3192C and T3234C were redundant
SNPs, that is, not causing a change in amino acids,
whereas nonredundant SNPs, that is, SNPs causing
change in amino acids, were SP-A1 C1101T (GCG:
alanine and GTG: valine) and SP-A2 A3265C (AAG:
lysine and CAG: glutamine). The alleles GCG
(SP-A1 1101), TAT (SP- A1 3192), GAT (SP-A1
3234), and CAG (SP-A2 3265) were significantly
associated with patients (Fig 1). The frequencies of
various genotypes in patients and control subjects
with respect to these four SNPs are shown in Figure
2. The mean values of the MDA (34.5% increase),
GSH (17.8% decrease), and LDH (40.6% increase)
for patients were significantly different from LAN
control subjects indicating increased oxidative dam-
age in patients (Table 4).
Table 1—Details of Primers Used for PCR Amplification*
Oligo (No.) Location S/AS Nt Position Sequence
SP-A1FF (1) Intron A S 469–488 5 ACTCCATGACTGACCACCTT 3
SP-A1,2FR (2) Intron E AS 3845–3865 5 TGCCACAGAGACCTCAGAGT 3
SP-A2FF (3) Intron 1 S 472–491 5 ATCACTGACTGTGAGAGGGT 3
SP-A1E2,3F (4) Intron A S 995–1014 5 GATGGGGTCACGGCCATCCC 3
SP-A1E2,3R (5) Intron C AS 1962–1991 5TGCCTCGTCCGCATTTCACCCTTCAGA CAGC 3
SP-A1E4F (6) Intron C S 2340–2361 5 TCGTGGCAGCAAGTGGGAGTCT 3
SP-A1E4R (7) Intron D AS 2654–2677 5 TCGGGGAAGTGAATTGTGTCTGCT 3
SP-A1E5F (8) Intron D S 2896–2919 5 TGAGGGAGGTGGCTTAGAGACAAA 3
SP-A1E5R (9) 3 UTR AS 3364–3385 5 GATGGAGGCCGACAAGGAGAGC 3
SP-A2E3,4F (10) Exon 3 S 1078–1097 5 GCTGTGCCCTCTGGCCCTTA 3
SP-A2E3,4R (11) Intron 4 AS 1980–2009 5TGCCTCGTCCGCATTCACCCTTCAGAC TGC 3
SP-A2E5F (12) Intron 4 S 2385–2406 5 ACTGGCCTGCCCCTCCTTCTGT 3
SP-A2E5R (13) Intron 5 AS 2577–2600 5 GCACGCTTGTTTGTCATCTCTATT 3
SP-A2E6F (14) Intron 5 S 2908–1931 5 TGAGGGAGGTGGCTTAGAGACAAA 3
SP-A2E6R (15) Exon 6 AS 3386–3404 5 CCTGGGGATGGAAACTGAA 3
SP-A2SSF (16) Exon 4 S 1602–1631 5TGCCTCGTCCGCATTCACCCTTCAGAC TGC 3
SP-A2SSR (17) Intron 4 AS 1980–2009 5TGCCTGGAGCCCCTGGTGTCCCTGGAGAGC 3
*Oligo  oligonucleotide; UTR untranslated region; Nt nucleotide; S  sense; AS  antisense; SP-A1FF name given to the primer based
on the details that it is forward primer to amplify SP-A1 full gene.
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Table 3—Comparison of Allele Frequencies at Variable Loci of SP-A1 and SP-A2 in Study Groups*
Locus
LAN Ctrl,
% Allele Freq
(No.)
LAN HAPE,
% Allele Freq
(No.)
HAN Ctrl,
% Allele Freq
(No.)
p Value
LAN Ctrl vs LAN HAPE LAN Ctrl vs HAN Ctrl
C1101T
T allele 91.7 (22) 63.6 (14) 80.0 (16)  0.001† (0.021)‡  0.018†
C allele 8.3 (2) 36.4 (8) 20.0 (4) 6.3 (2.8–14.3)§ 2.8 (1.2–6.5)§
C1193G
G allele 46.7 (14) 33.3 (8) 8.3 (2) 0.053 (0.338)‡  0.001†
C allele 53.3 (16) 66.7 (16) 91.7 (22) 1.8 (0.9–3.1)§ 9.7 (4.3–22.0)§
C1416T
C allele 92.9 (26) 91.7 (22) 79.2 (19) 0.750 (0.807)‡  0.005†
T allele 7.1 (2) 8.3 (2) 20.8 (5) 1.2 (0.4–3.4)§ 3.4 (1.4–8.5)§
T3138C
T allele 90.0 (18) 100.0 (10) 77.8 (14) 0.001 (0.322)‡  0.018†
C allele 10.0 (2) 0.0 (0) 22.2 (4) 0 2.6 (1.1–5.7)§
T3192C
C allele 85.0 (17) 38.9 (7) 62.5 (10)  0.001† (0.003)‡  0.001†
T allele 15.0 (3) 61.1 (11) 37.5 (6) 8.9 (4.5–17.6)§ 3.4 (1.7–6.7)§
T3234C
C allele 85.0 (17) 38.9 (7) 62.5 (10)  0.001† (0.003)‡  0.001†
T allele 15.0 (3) 61.1 (11) 37.5 (6) 8.9 (4.5–17.6)§ 3.4 (1.7–6.7)§
G1649C
G allele 40.0 (12) 29.2 (7) 20.8 (5) 0.108 (0.486)‡  0.003†
C allele 60.0 (18) 70.8 (17) 79.2 (19) 1.6 (0.9–2.9)§ 2.5 (1.4–4.8)§
C2474T
C allele 93.7 (15) 100.0 (22) 83.3 (20) 0.011 (0.211)‡  0.02†
T allele 6.3 (1) 0.0 (0) 16.7 (4) 0 2.9 (1.1–7.8)§
A2491C
A allele 96.7 (29) 100.0 (22) 83.3 (20) 0.067 (0.712)‡  0.001†
C allele 3.3 (1) 0.0 (0) 16.7 (4) 0 5.9 (1.7–19.8)§
A3265C
A allele 37.5 (9) 21.4 (3) 36.4 (8)  0.012† (0.175)‡ 0.872 (0.881)‡
C allele 62.5 (15) 78.6 (11) 63.6 (14) 2.2 (1.2–4.1)§ 1.0 (0.6–1.9)§
*Values in parentheses are No., unless otherwise indicated. Ctrl  control; Freq  frequency.
†Value is statistically significant according to 2  2 table.
‡Value in parentheses is OR.
§Value in parentheses is 95% CI.
Table 2—Nature of Polymorphisms Observed in SP-A1 and SP-A2 in the Present Study*
Gene Location
Nucleotides Amino Acid
Position Change Position Change
SP-A1 Signal peptide 1101 C/T 19th Val to Ala
SP-A1 Exon 2 1162 C/T 39th His to His
SP-A1 Exon 2 1193 C/G 50th Leu to Val
SP-A1 Intron B 1416 C/T
SP-A1 Exon 3 1544 G/A
SP-A1 Exon 5 3138 T/C 184th Tyr to Tyr
SP-A1 Exon 5 3192 T/C 202nd Asp to Asp
SP-A1 Exon 5 3234 T/C 216th Pro to Pro
SP-A2 Intron 3 1382 C/G
SP-A2 Intron 3 1492 T/C
SP-A2 Exon 4 1649 G/C 91st Ala to Pro
SP-A2 Exon 4 1660 A/G 94th Arg to Arg
SP-A2 Exon 5 2474 C/T 114th Phe to Phe
SP-A2 Exon 5 2491 C/A 120th Gln to Pro
SP-A2 Exon 6 3018 T/C 140th Ser to Ser
SP-A2 Exon 6 3265 A/C 223th Gln to Lys
*Nucleotide positions of SP-A1 and SP-A2 are according to the gene sequences reported in Entrez Nucleotide (National Center for Biotechnology
Information) [Accession No. M 30838 and M 68519, respectively].
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The frequency of the GCG and GNG genotypes
with respect to nonredundant SNP SP-A1 C1101T
was more, whereas that of GTG was less in patients
in comparison with control subjects (Fig 2, top left,
A). The single HAPE patient with the GCG geno-
type showed increased oxidative damage in compar-
ison with the GTG patients, exhibited by increased
MDA (10.6%) and decreased GSH (15.3%) [Fig 3].
However, the LDH value showed a decrease of
87.7%, indicating less tissue injury in comparison
with GTG patients. The GNG patients showed
decreased oxidative damage, suggesting heterozy-
gote advantage (MDA value was lower by 10.1%,
GSH value was higher by 29%, and LDH value was
lower by 44% in comparison with GTG patients) [Fig
3]. A correlation of biochemical parameters with the
redundant SNPs SP-A1 T3192C and SP-A1 T3234C
could not be established, although these two SNPs
appear to be always coexisting.
As observed with nonredundant SNP SP-A1
C1101T, the NAG patients, with respect to nonre-
dundant SNP SP-A2 A3265C, showed decreased
oxidative damage as indicated by a 15.9% decrease in
the MDA level, a 15.6% increase in the GSH level,
and a 24.0% decrease in the LDH level in compar-
ison with the CAG patients (Fig 3). Interestingly, the
patients heterozygous at SP-A1 C1101T were also
heterozygous at SP-A2 A3265C. Also, the mean
value of MDA was 17.8% lower, the mean GSH level
was 24% higher, and the mean LDH level was 11.6%
lower in these double heterozygous patients (at both
SP-A1 C1101T and SP-A2 A3265C loci) in compar-
ison with patients who were homozygous for either
allele at both these loci.
In the HAN control subjects, the mean values of
MDA were lower and the mean values of GSH were
higher in comparison with the LAN control subjects.
Significant genetic differences were observed at six
of eight variable loci in SP-A1 (C1101T, C1193G,
C1416T, T3138C, T3192C, and T3234C) and three
Figure 1. Percentage of patients from the total subjects (, LAN controls and f, HAPE patients) with
a specific allele at SP-A1 C1101T, SP-A1 C3192T, SP-A1 C3234T, and SP-A2 A3265C. Statistically
significant association of GCG, TAT, GAT, and CAG alleles was observed with patients in comparison
with control subjects. OR and p values are shown above the bars. N number of alleles.
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of eight variable loci in SP-A2 (G1649C, C2474T,
and A2491C) [Tables 3, 4].
Discussion
The present study investigated the association of
SNPs in SP-A1 and SP-A2 with HAPE in Indian
LAN subjects on sojourn to high altitude. A total of
16 variable loci (eight each in SP-A1 and SP-A2)
were observed in subjects. Of these 16 SNPs, 5 SNPs
in SP-A1 (C1101T, G1544A, T3138C, T3192C, and
T3234C) and 3 SNPs in SP-A2 (C2491A, T3018C,
and A3265C) are being reported for the first time.
Three exonic SNPs in SP-A1 (C1101T, T3192C,
and T3234C) and one in SP-A2 (A3265C) showed
statistically significant association with HAPE in
LAN sojourners. The SNP SP-A1 C1101T is a
nonredundant SNP present in the signal peptide
region causing a change in amino acid from valine
(GTG) to alanine (GCG). Because the signal peptide
Table 4—LDH, MDA, and GSH Levels in HAN Control Subjects, LAN Control Subjects, and LAN HAPE Groups*
Parameters
HAN (Control Subjects)
(n  19)
LAN (Control Subjects)
(n  15)
LAN (HAPE)
(n  12)
LDH, U/L 169.0  7.7 160.1 6.0 225.1 18.2†
MDA, mol/L 4.5  0.2 5.6 0.2‡ 7.6 0.3†
GSH, mg % 37.2  1.5 32.5 1.1‡ 26.7 1.4†
*Values given as the mean  SE.
†Values are significantly different between LAN HAPE and LAN controls at p values  0.05.
‡Values are significantly different between HAN controls and LAN controls at p values  0.05.
Figure 2. Percentage of subjects (, LAN control subjects and f, HAPE patients) with various
genotypes at polymorphisms observed in SP-A1 and SP-A2. Distribution of genotypes in LAN control
subjects and HAPE patients with respect to SP-A1 C1101T (top left, A), SP-A1 T3192C (top right, B),
SP-A1 T3234C (bottom left, C), and SP-A2 A3265C (bottom right, D).
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is important for correct protein targeting, C1101T
may adversely affect the normal protein targeting.
The only patient who was found homozygous for
the GCG allele showed increased oxidative dam-
age as compared with GTG patients. The clinical
history of this patient revealed that he had suf-
fered five episodes of HAPE on reinduction to a
high altitude during the last 10 years. Although no
conclusive statement can be drawn with a single
patient, the recurrence of the HAPE and the
severity of biochemical parameters suggest a pos-
sible role for the GCG allele in predisposing
subjects to HAPE. The absence of GCG homozy-
gotes in the control subjects and the small number
of GCG homozygotes observed in patients indi-
cates that the GCG allele may lead to a probable
alteration in a vital function.
The other two redundant SNPs of SP-A1 showing
significant association with HAPE (SP-A1 T3192C
and SP-A1 T3234C) are present in the carbohydrate
recognition domain of SP-A, which participates in
lipid binding and pH-dependent lipid aggregation
needed for a homogeneous surfactant layering at the
air-liquid interface.20,21 However, the levels of
MDA, GSH, and LDH were not significantly differ-
ent in patients carrying different alleles, suggesting
that SP-A1 T3192C and SP-A1 T3234C could be
simply surrogate markers. The coexistence of TAC
(SP-A1 T3192C) with GAC (SP-A1 T3234C) geno-
types and, also, their heterozygotes in all of the
subjects indicate that they may be in linkage disequi-
librium with each other.
SP-A2 A3265C, located in exon 6 of SP-A2 coding
for the carbohydrate recognition domain, leads to a
change in amino acid from glutamine to lysine. Both
the CAG allele (coding for glutamine) and the CAG
genotype were associated with patients, and the
CAG patients showed increased oxidative damage in
comparison with the NAG patients suggesting that
the CAG allele may be genetically predisposing the
LAN subjects to HAPE.
The heterozygotes at SP-A1 C1101T and at SP-A2
A3265C showed reduced oxidative damage, which
suggests a heterozygote advantage. All of the patients
who were heterozygous at locus SP-A1 C1101T were
also heterozygous at locus SP-A2 A3265C, and these
double-heterozygous subjects showed additionally
decreased oxidative damage, which indicates that
heterozygosity at both of these loci may have a
synergistic effect. The observation is supported by
the fact that SP-A is composed of gene products of
both SP-A1 and SP-A2.
The SNPs SP-A2 G1649C and SP-A2 A1660G,
associated with patients of allergic bronchopulmo-
nary aspergillosis and pulmonary tuberculosis in
our earlier studies, did not show association with
Figure 3. Levels of biochemical parameters in patients (, LAN control subjects and f, HAPE
patients) with various genotypes at SP-A1 C1101T (GTG, homozygous for T allele; GNG, heterozygous
for C/T alleles; and GCG, homozygous for C allele) and SP-A2 A3265C (CAG, homozygous for C allele;
and NAG, heterozygous for A/C alleles). Left, A: levels of MDA. Middle, B: levels of GSH. Right, C:
levels of LDH.
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HAPE patients.10,11 SP-A1 C1193G (Leu to Val)
was identified as one of the polymorphisms asso-
ciated with tuberculosis in the Mexican popula-
tion;22 however, in the present study we did not
find any significant association of this SNP with
HAPE.
The lung functions of highlanders have been
observed to be superior to the lowlanders, and
genetic differences among the HAN and LAN
populations might have a role in the distinct
mechanisms of high-altitude acclimatization of
these ethnically segregated populations.23 The
SNP profile of SP-A1 and SP-A2 of the LAN and
HAN populations varied significantly, which sug-
gests that two populations are genetically very
different from each other with respect to these two
genes. However, the frequency of susceptibility
alleles of SP-A1 and SP-A2 in HAN control sub-
jects was lower than in the LAN HAPE subjects, as
expected (allele frequency of C allele of SP-A1
C1101T in LAN HAPE subjects, 36.3% and in
HAN control subjects, 20%; allele frequency of C
allele of SP-A2 C2474T in LAN HAPE subjects,
100% and in HAN control subjects, 83.3%; allele
frequency of A allele of SP-A2 A2491C in LAN
HAPE subjects, 100% and in HAN control sub-
jects, 83.3%; allele frequency of C allele of SP-A2
A3265C in LAN HAPE subjects, 78.6% and in
HAN control subjects, 63.6%). Such genetic dif-
ferences in the HAN and LAN populations with
respect to other genetic loci, such as the renin-
angiotensin system and the 	-2-andrenergic re-
ceptor alleles, have been reported earlier.24,25
The mean values of two biochemical parameters
for oxidative damage, namely, MDA and GSH,
showed that in the HAN control subjects there was
lower oxidative damage in comparison with the
LAN control subjects as observed by the de-
creased MDA levels, and perhaps it was on ac-
count of the increased GSH levels. To date, there
are no studies comparing the LAN and HAN
populations with respect to their response to
high-altitude-induced oxidative stress.
The exposure of the lung surfactant to high-
altitude-induced oxidative stress may result in the
peroxidation of unsaturated phospholipids, surfac-
tant inactivation, airspace collapse, and impaired gas
exchange. SP-A protects surfactant phospholipids
from oxidative damage.6 Oxidative stress, such as
ozone exposure of SP-A gene variants, resulted in the
production of significantly different amounts of
proinflammatory cytokines interleukin-8 and tumor
necrosis factor-.12 The results of the present study
propose that genetic variants of SP-A1 (C1101T,
T3192C, and T3234C) and SP-A2 (A3265C) are
associated with HAPE in LAN sojourners in the
Indian population. Furthermore, two of the alleles
GCG (SP-A1 C1101T) and CAG (SP-A2 A3265C)
may have adverse effects on the protective role of
SP-A against oxidative damage, because higher levels
of MDA and LDH and lower levels of GSH were
observed in HAPE patients carrying these polymor-
phisms.
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